Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

20.68 -0.35 (-1.66%)
Streaming Delayed Price Updated: 1:32 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 579,834
Open 20.52
Bid (Size) 20.68 (6)
Ask (Size) 20.69 (4)
Prev. Close 21.03
Today's Range 20.52 - 20.75
52wk Range 17.23 - 30.06
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill

Performance

YTD
-1.5%
-1.5%
1 Month
+2.0%
+2.0%
3 Month
-7.8%
-7.8%
6 Month
+1.0%
+1.0%
1 Year
-30.6%
-30.6%

More News

Read More
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors
Via Chartmill
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
Breaking Down Genmab: 4 Analysts Share Their Views
Via Benzinga
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?.
Via Chartmill
Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB)
Via Chartmill
Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability.
Via Chartmill
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Via Stocktwits
Topics Stocks
Exposures US Equities
What Analysts Are Saying About Genmab Stock
Via Benzinga
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy?
Via Chartmill
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Via Benzinga
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
From Genmab A/S
Via Business Wire
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
From Genmab
Via Business Wire
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Via Benzinga
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
From Genmab A/S
Via Business Wire
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
In a market where value is scarce, NASDAQ:GMAB offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?
Yes, Genmab A/S - American Depositary Shares is publicly traded.
What exchange does Genmab A/S - American Depositary Shares trade on?
Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Genmab A/S - American Depositary Shares?
The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
What is the current price of Genmab A/S - American Depositary Shares?
The current price of Genmab A/S - American Depositary Shares is 20.68
When was Genmab A/S - American Depositary Shares last traded?
The last trade of Genmab A/S - American Depositary Shares was at 05/23/25 01:32 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.